The Effects of Ifosfamide, Carboplatin, and Etoposide in Children with Recurrent/Refractory Solid Tumors.
- Author:
Gil Soon CHOE
1
;
Geong Young KIM
;
Ki Joong KIM
;
Hahng LEE
Author Information
1. Department of Pediatrics, College of Medicine, Hanyang University, Seoul, Korea. h251406@hmc.hanyang.ac.kr
- Publication Type:Original Article
- Keywords:
Ifosfamide;
Carboplatin;
Etoposide;
Effect;
Recurrent/refractory solid tumors
- MeSH:
Carboplatin*;
Child*;
Drug Therapy;
Etoposide*;
Granulocyte Colony-Stimulating Factor;
Humans;
Ice;
Ifosfamide*;
Incidence;
Medical Records;
Medulloblastoma;
Nausea;
Neuroblastoma;
Neutrophils;
Osteosarcoma;
Rhabdomyosarcoma;
Vomiting
- From:Korean Journal of Pediatric Hematology-Oncology
2001;8(2):273-280
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The purpose of this study was to evaluate the effects of ifosfamide, carboplatin, etoposide (ICE) regimen in children with recurrent/refractory solid tumors. METHODS: The medical records of 7 patients diagnosed with recurrent/refractory solid tumors, including osteosarcoma in 2 patients, rhabdomyosarcoma in 2, neuroblastoma in 2 and medulloblastoma in one, and followed at Hanyang University Hospital from January, 1995 until May, 2001, were reviewed. The hematological toxicities above grade III, non-hematological toxicities above grade II, and response rate [complete response (CR) partial response (PR)] after several courses of ifosfamide 1,800 mg/m2/day (day 0 through 4 each cycle), carboplatin 400 mg/m2/day (day 0, 1), etoposide 100 mg/m2/day (day 0 through 4 each cycle) were evaluated. RESULTS: The incidences of hematological toxicities above grade III and non-hematological toxicities above grade II were 89% and 18%, respectively over the total 56 courses of ICE plus granulocyte colony-stimulating factor (G-CSF: 5.0mug/kg/day). Median time from the start of ICE chemotherapy to absolute neutrophil count (ANC) > or =1,000/mm3 for all patients during the total courses was 15 days. Seven patients evaluated for response to ICE. The overall response rate (CR PR) in this study was 57%. The CR rate for all diagnostic categories was 43%. CONCLUSION: Our study indicates that myelosuppression was the major toxicity of ICE chemotherapy and non-hematological toxicity was 20% of hematological toxicity except nausea and vomiting. The combination of ICE chemotherapy was associated with a high CR rate (43%) in children with recurrent/refractory solid tumors.
